PRESKORN and MACALUSO: University of Kansas School of Medicine, Wichita, KS; MEHRA: Artemis Institute for Clinical Research, San Diego, CA; ZAMMIT: CliniLabs, New York, NY; MOSKAL: Dept Biomedical Engineering, Falk Center for Molecular Therapeutics, McCormick School of Engineering and Applied Sciences, Northwestern University, and Naurex Inc, Evanston, IL; BURCH: Naurex Inc, Evanston, IL

Acknowledgements. The GLYX-13 Clinical Study Group Principal Investigators were Misha Backonja, MD, Lifetree Clinical Research, Salt Lake City, UT; Daniel Greuner, MD, Lifetree Clinical Research, Philadelphia, PA; Paul Gross, MD, Lehigh Center for Clinical Research, Allentown, PA; David Krefetz, DO, Lifetree Clinical Research, Willingboro, NJ; Benji Kurian, MD, University of Texas Southwestern Medical Center, Dallas, TX; Michael Lesem, MD, Claghorn-Lesem Clinical Research Ltd, Houston, TX; Matthew Macaluso, DO, and Sheldon Preskorn, MD, University of Kansas School of Medicine, Wichita, KS; Raymond Manning, MD, CNRI-LA, Pico Rivera, CA; Vishaal Mehra, MD, Artemis Institute for Clinical Research, San Diego, CA; Rick Mofsen, MD, CRI Worldwide LLC, St Louis, MO; and Gary Zammit, PhD, Clinilabs, New York, NY.

Funding for this study was provided in its entirety by Naurex, Inc, 1801 Maple Avenue, Suite 4300, Evanston IL 60201, which owns patents, patent applications, and commercialization rights to GLYX-13. Dr. Burch is an employee of Naurex and has received financial compensation and stock. Drs. Macaluso, Mehra, Preskorn, and Zammit were paid clinical investigators for Naurex. During the past 12 months, Dr. Preskorn has been a consultant for AssureX, Delphor, Eisai, Johnson & Johnson, Merck, Naurex, Sunovion, and Tashio. Dr. Moskal is the founder of Naurex, Inc. He has founders' shares of stock in the company and receives financial compensation as a consultant.

Clinical trial registration. Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression, http://www.clinicaltrials.gov/ct2/show/NCT01234558?term=Naurex&rank=2,NCT01234558; Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers, http://www.clinicaltrials.gov/ct2/show/NCT01014650?term=Naurex&rank=3,NCT01014650.

Note: Portions of this column are adapted with permission from Moskal et al. 2014.9

Please send correspondence to: Ronald M Burch, MD, PhD, Naurex, Inc, 1801 Maple Avenue, Suite 4300, Evanston IL, 60201ronburch@naurex.com